3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Withdrawn
1
Terminated
1
Sponsor Class
OTHER
5
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Gynecologic
1
CNS
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Neoplasm Metastasis
1
Gastrointestinal Neoplasms
1
Colonic Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
pembrolizumab
1019
Carboplatin
959
Paclitaxel
932
Gemcitabine
793
Cisplatin
748
Docetaxel
682
Bevacizumab
610
Pemetrexed
502
Nivolumab
486
Cyclophosphamide
466
Capecitabine
461
Fluorouracil
417
Dexamethasone
402
Rituximab
372
Oxaliplatin
347
Injections
342
atezolizumab
297
Trastuzumab
297
Leucovorin
286
Cetuximab
282
Irinotecan
266
130-nm albumin-bound paclitaxel
252
Prednisone
244
Doxorubicin
240
Ipilimumab
226
Lenalidomide
220
Fulvestrant
217
fludarabine
214
durvalumab
205
Erlotinib Hydrochloride
188
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Interventional
×
Mebendazole
×
Clear all
NCT02201381
2022-07-18
METRICS
Health Clinics Limited
Phase 3
Withdrawn
NCT03628079
2020-01-22
RepoMeb
Repos Pharma
Phase 1/2
Terminated
11 enrolled